

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com | www.triochemproducts.com Corporate Identity Number : L24249MH1972PLC015544

> Ref No: TPL PP 1224 2019 14th February, 2020

> > Page | 1

To

Corporate Relationship Department

Bombay Stock Exchange Limited

P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

Fax No.: 022 - 22722037 / 2039 / 2041 / 2061 / 3121 / 3719

Sub: Outcome of the Board - Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015 Ref: Security Code No.512101 - ISIN No.: INE 331 E 01013

Dear Sir / Madam,

Pursuant to Notice of Board meeting dated 3rd February, 2020 the Board meeting was held on today Friday, 14th February, 2020 at 4.00 p.m. at 4th Floor, Samabav Chambers, Sir P. M. Road, Fort, Mumbai: 400001 and has approved the following:

- The Board discussed and approved the Unaudited Financial Results of the Company for the quarter and nine month ended on 31st December, 2019 duly reviewed by the Audit Committee along and the auditor's report thereon in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- The Report on Limited Review of the financial results for the quarter and nine month ended on 31st December, 2019 is also discussed.
- 3. The Board discussed and approved the Statement of Deviation or Variation in Public issue, Rights Issue, Preferential issue, etc. for the quarter ended 31st December, 2019, duly reviewed by the Audit Committee along and the auditor's comments thereon in accordance with Regulation 32(1), 32(2) and 32(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 4. The Board took note on Register of contracts with related party and contracts and Bodies etc. in which directors are interested [Pursuant to section 189(1) and rule 16(1)] [Form MBP-4]. (A) Contract or agreements with any related party under section 188 or in which any director is concerned or interested under sub-section (2) of section 184 for the quarter ended 31st December, 2019. (B) Name of the bodies



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com | www.triochemproducts.com Corporate Identity Number : L24249MH1972PLC015544

corporate, firms or other association of individuals as mentioned under sub-section (1) of section 184, in

which any director is having any concern or interest for the quarter ended 31st December, 2019.

- 5. Take notes on the compliance for the quarter and nine month ended 31st December, 2019
- 6. Board Meeting commenced at 4.00 p.m. and concluded at 4.50 p.m.


You are requested to take note of the same.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA DIRECTOR & CEO DIN: 00312369



Chartered Accountants

Pune Address : 123. Sohrab Hall. 21 Sassoon Road, Opp. Jehangir Hospital. Pune - 411001 • T : 020 4906 7177 E : info@kdg.co.in • W : www.kdg.co.in

Independent Auditor's Review Report on Quarterly and Nine Months Ended Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("Company")

- 1. We have reviewed the accompanying statement of unaudited financial results TRIOCHEM PRODUCTS LIMITED ("Company") for the quarter and year to date ended December 31, 2019 together with notes thereon (the 'Statement') attached herewith, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time. The statement is the responsibility of the Company's management and has been approved by Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind As 34"), specified under Section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/PAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India.
- 2. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP Chartered Accountants Firm Registration No: 104746W/W100096

Kunal Vakharia Partner Membership No.: 148916 UDIN: 2014と916AAAAAU5152 Place: Mumbai Date: 14th February, 2020



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com | www.triochemproducts.com Corporate Identity Number : L24249MH1972PLC015544

TRIOCHEM PRODUCTS LIMITED

Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com

CIN: L24249MH1972PLC015544

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2019

Sr.	Particulars		Quarter Ended	1	Nine Mor	Year Ended	
No.		31-Dec-19	30-Sep-19	31-Dec-18	31-Dec-19	31-Dec-18	31-Mar-19
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income				, , ,	, ,	/
	(a) Revenue from Operations	541.16	261.76	194.84	855.52	895.50	1,235.47
	(b) Other Income	12.93	0.16	1.12	13.25	3.99	5.52
	Total Income From Operations	554.09	261.92	195.95	868.77	899.48	1,240.99
2	Expenses						
	(a) Cost of Materials Consumed	424.70		41.84	424.70	641.40	1,099.78
	(b) Purchase of stock in trade	4.78		49.60	4.78	55.60	55.60
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(99.57)	166.65	45.72	102.98	(51.59)	(311.83
	(d) Employees Benefit Expenses	17.04	19.36	19.80	51.92	54.29	71.90
	(e) Finance Costs	9.36	2.67	11.63	17.19	37.46	45.40
	(f) Depreciation and Amortisation Expenses	4.21	4.20	5.16	12.57	15.43	20.5
	(g) Other Expenditure	27.33	26.68	36.64	84.93	108.75	155.59
	Total expenses	387.85	219.56	210.41	699.08	861.36	1,137.0
	Profit before exceptional items and tax	166.24	42.36	(14.46)	169.69	38.12	103.9
	Exceptional items						-
	Profit/ (Loss) before tax	166.24	42.36	(14.46)	169.69	38.12	103.95
	Tax Expense						
	(a) Current tax	41.73	2.29	(5.15)	44.02	10.60	30.75
	(b) Deferred tax	1.71	7.27	(0.10)	(1.80)	(4.42)	(1.10
	Total tax expenses	43.44	9.56	(5.25)	42.22	6.18	29.6
	Net Profit/ (Loss) for the period	122.80	32.80	(9.21)	127.47	31.94	74.30
	Other Comprehensive Income (Net of Taxes)						
	(A)(i). Items that will be reclassified to profit or loss						
	(ii). Income tax relating to items that will be reclassified to profit or loss					·	
	(B)(i). Item that will not be reclassified to profit or loss	(0.03)	(0.30)	1.11	(0.32)	0.16	0.02
	(ii). Income tax relating to items that will not be reclassified to profit or loss	0.00	0.09	(0.29)	0.08	(0.04)	(0.0)
	Total other Comprehensive Income (net of taxes)	(0.03)	(0.21)	0.82	(0.24)	0.12	0.01
	Total Comprehensive Income for the period	122.77	32.59	(8.39)	127.23	32.06	74.31
0	Paid-up equity share capital (Face Value of ₹ 10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
- 1	Other equity as per Balance Sheet of previous accounting year						853.0
	Earnings per equity share (EPS) (of Rs. 10/- each) (not annualised)						
	Basic / Diluted EPS (in Rs.)	50.12	13.39	(3.76)	52.03	13.04	30.33



9-----

Factory : Plot No. 10/2, MIDC Industrial Area, Morivali, Ambernath (West), Dist. Thane, PIN - 421 501 MAHARASHTRA. Tel. : 0251-268 2191 * 268 2711 | Fax : 0251-268 2192 | Email : info@amphray.com Page 1 of 2



5

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com | www.triochemproducts.com Corporate Identity Number : L24249MH1972PLC015544

Notes: 1) The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14th February, 2020. The Statutory auditors of the company has carried out a limited review of aforesaid results. 2) The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019. The effect on adoption of Ind AS 116 on the financial results is insignificant. 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals the disclosure requirement of Indian Accounting Standard (IND AS-108) Segment Reporting" is not applicable. 4) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary. FOR TRIOCHEM PRODUCTS LIMITED RAMU S. DEORA Place: Mumbai **DIRECTOR & CEO** DIN: 00312369

Dated: 14th February, 2020







MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com | www.triochemproducts.com Corporate Identity Number : L24249MH1972PLC015544

TRIOCHEM PRODUCTS LIMITED

Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com

CIN: L24249MH1972PLC015544

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2019

Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31-Dec-19	30-Sep-19	31-Dec-18	31-Dec-19	31-Dec-18	31-Mar-19
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Net Operating Income	554.09	261.92	195.95	868.77	899.48	1,240.09
2	Profit / (Loss) for the period (before Interest, Depreciation, Taxes, Exceptional and / or Extraordinary items)	179.81	49.23	2.33	199.45	91.01	169.95
3	Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	166.24	42.36	(14.46)	169.69	38.12	103.95
í	Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	122.80	32.80	(9.21)	127.47	31.94	74.30
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(0.03)	(0.21)	0.82	(0.24)	0.12	0.01
5	Equity share capital (Face value of Rs.10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
7	Reserve (excluding Revaluation Reserves as shown in the Balance Sheet of previous year)						853.07
	Earnings per equity share (EPS) (of Rs. 10/- each) (for continuing and discontinued operations)						
	a) Baisc (not annualized)	50.12	13.39	(3.76)	52.03	13.04	30.33
	b) Diluted (not ammualized)	50.12	13.39	(3.76)	52.03	13.04	30.33

1) The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14th February, 2020. The Statutory auditors of the company has carried out a limited review of aforesaid results.

2) The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019. The effect on adoption of Ind AS 116 on the financial results is insignificant.

3) The Company operates in single segment only, i.e. chemical and pharmaceuticals the disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.

4) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

5) The above is an extract of the detailed format of quarterly and half year ended financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of the quarterly and half year ened financial results are available on the on the Stock Exchange and the Company namely www.bseindia.com and www.triochemproducts.com

FOR TRIOCHEM PRODUCTS LIMITED

6

RAMU S. DEORA DIRECTOR & CEO DIN: 00312369

Place: Mumbai

00

Dated: 14th February, 2020

Factory : Plot No. 10/2, MIDC Industrial Area, Morivali, Ambernath (West), Dist. Thane, PIN - 421 501 MAHARASHTRA. Tel. : 0251-268 2191 * 268 2711 | Fax : 0251-268 2192 | Email : info@amphray.com Page 1 of 1

AL ASS

MUMBAI



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com | www.triochemproducts.com Corporate Identity Number : L24249MH1972PLC015544

> Ref No: TPL PP 1226 2019 Dated 14th February, 2020

The Corporate Relationship Department, BSE Limited 1st Floor, P J Towers, Dalal Street, Mumbai: 400023.

Dear Sir,

To

Sub: Submission of Statement of Deviation or Variation in Public Issue, Rights issue, Preferential issue, etc under Regulation 32(1) of the SEBI (Listing Obligation & Disclosures Requirement) Regulation, 2015. Ref: Security Code No. 512101 - ISIN No.: INE 331 E 01013.

Please find enclosed herewith the statement of deviation or variation in public issue, rights issue, preferential issue, etc. under Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended 31st December, 2019 as amended as per Circular No. CIR/CFD/CMD1/162/2019 Dated 24th December, 2019

We request you to kindly take the above on records and acknowledge the receipt of the same.

Thanking you and assuring you of our best co-operation at all times.

Yours faithfully,

DIN: 00312369

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA DIRECTOR & CEO

Factory : Plot No. 10/2, MIDC Industrial Area, Morivali, Ambernath (West), Dist. Thane, PIN - 421 501 MAHARASHTRA. Tel. : 0251-268 2191 * 268 2711 | Fax: 0251-268 2192 | Email : info@amphray.com

Page 1 of 2



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com | www.triochemproducts.com

Corporate Identity Number : L24249MH1972PLC015544

STATEMENT OF DEVIATION OR VARIATION IN UTILISATION OF FUNDS RAISED

(Pursuant to Regulation 32(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015

Name of listed entity	TRIOCHEM PRODUCTS LIMITED
Mode of Fund Raising Public Issues / Rights Issues / Preferential Issues / QIP / Others	Not Applicable
Date of Raising Fund	
Amount Raised	
Report filed for Quarter ended	31-12-2019
Monitoring Agency Applicable / Not Applicable	
If there a Deviation / Variation in use of funds raised Yes / No $$	•
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the Shareholders	•
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	The statement of Category wise variation is also not applicable as there has been no offer made by way of Public Issue, Rights Issue, Preferential Issue, etc., during the Quarter ended 31 st December, 2019
Comments of the auditors, if any	Not Applicable. As there is no offer made by way of Public Issue, Right Issue, Preferential Issue, etc.,

Objects for which funds have been raised and where there has been a deviation, in the following table: Not Applicable

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation / Variation for the quarter according to applicable object.	
•						

Deviation or variation could mean:

(a) Deviation in the object or purpose for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising documents i.e. prospectus, letter of offer, etc.

Name of Signatory: Designation:

RAMU S. DEORA DIRECTOR & CEO (DIN: 00312369)

Factory : Plot No. 10/2, MIDC Industrial Area, Morivali, Ambernath (West), Dist. Thane, PIN - 421 501 MAHARASHTRA. Tel.: 0251-268 2191 • 268 2711 | Fax: 0251-268 2192 | Email: info@amphray.com

Page 2 of 2

8